UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

A recent publication from IMDEA Materials Institute and the Technical University of Madrid (UPM) presents a major step ...

Cadence’s dual announcements with NVIDIA and Google mark pragmatic steps in the industry’s transition toward intelligent, ...

Researchers in Spain have identified a new source of underperformance in utility-scale PV plants caused by “suboptimal ...